Drug intelligence / Profile preview

STM-416p

Development stage: Phase 1
Lead developer: SURGE Therapeutics
Modality: Hydrogel Systems → Drug Delivery Systems, Small Molecules
Administration: Intraoperative, Intralesional

Overview

STM-416p is an intraoperative immunotherapy being developed by SURGE Therapeutics for prostate cancer patients undergoing radical prostatectomy. It utilizes SURGE's injectable biodegradable hydrogel technology to enable extended, localized release of resiquimod (an imidazoquinolinamine that targets TLR7 and TLR8) directly at the site of surgical tumor resection. This approach aims to reprogram the body's response to surgery from immunosuppressive to immunostimulatory, triggering the patient's immune system to destroy residual cancer cells and prevent recurrence.

Targets

TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on STM-416p.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STM-416p.

Explore the full profile